Home/Filings/4/0000899243-22-031351
4//SEC Filing

TYSON TIMOTHY 4

Accession 0000899243-22-031351

CIK 0001537917other

Filed

Sep 15, 8:00 PM ET

Accepted

Sep 16, 6:00 PM ET

Size

24.5 KB

Accession

0000899243-22-031351

Insider Transaction Report

Form 4
Period: 2022-09-16
Transactions
  • Disposition to Issuer

    Director Stock Option - Option to buy

    2022-09-1650,0580 total
    Exercise: $4.10Exp: 2022-11-21Common Stock (50,058 underlying)
  • Disposition to Issuer

    Director Stock Option - Option to buy

    2022-09-1665,0000 total
    Exercise: $1.22Exp: 2030-08-19Common Stock (65,000 underlying)
  • Disposition to Issuer

    Director Stock Option - Option to buy

    2022-09-1675,0000 total
    Exercise: $2.90Exp: 2028-05-24Common Stock (75,000 underlying)
  • Disposition to Issuer

    Director Stock Option - Option to buy

    2022-09-1688,0000 total
    Exercise: $1.10Exp: 2031-08-23Common Stock (88,000 underlying)
  • Disposition to Issuer

    Director Stock Option - Option to buy

    2022-09-1625,0000 total
    Exercise: $8.75Exp: 2026-05-09Common Stock (25,000 underlying)
  • Disposition to Issuer

    Director Stock Option - Option to buy

    2022-09-1650,0000 total
    Exercise: $2.33Exp: 2028-08-26Common Stock (50,000 underlying)
  • Disposition to Issuer

    Director Stock Option - Option to buy

    2022-09-1650,0000 total
    Exercise: $1.18Exp: 2029-08-22Common Stock (50,000 underlying)
  • Disposition to Issuer

    Director Stock Option - Option to buy

    2022-09-1688,0000 total
    Exercise: $0.31Exp: 2032-08-23Common Stock (88,000 underlying)
  • Disposition to Issuer

    Common Stock

    2022-09-165,8650 total
Footnotes (9)
  • [F1]Disposed of pursuant to the merger agreement between the issuer and Syros Pharmaceuticals, Inc. ("Syros") in exchange for 257 shares of Syros common stock having a market value of $7.30 per share at the close of trading on September 15, 2022, the last trading day immediately preceding the effective time of the merger, but after giving effect to a 1-for-10 reverse stock split by Syros (the "Reverse Split"), with cash paid in lieu of fractional shares.
  • [F2]This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,232 shares of Syros common stock for $93.56 per share, after giving effect to the Reverse Split.
  • [F3]This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 1,094 shares of Syros common stock for $199.68 per share, after giving effect to the Reverse Split.
  • [F4]This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 3,286 shares of Syros common stock for $66.18 per share, after giving effect to the Reverse Split.
  • [F5]This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,191 shares of Syros common stock for $53.17 per share, after giving effect to the Reverse Split.
  • [F6]This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,191 shares of Syros common stock for $26.93 per share, after giving effect to the Reverse Split.
  • [F7]This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,848 shares of Syros common stock for $27.84 per share, after giving effect to the Reverse Split.
  • [F8]This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 3,856 shares of Syros common stock for $25.10 per share, after giving effect to the Reverse Split.
  • [F9]This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 3,856 shares of Syros common stock for $7.07 per share, after giving effect to the Reverse Split.

Issuer

TYME TECHNOLOGIES, INC.

CIK 0001537917

Entity typeother

Related Parties

1
  • filerCIK 0001207405

Filing Metadata

Form type
4
Filed
Sep 15, 8:00 PM ET
Accepted
Sep 16, 6:00 PM ET
Size
24.5 KB